Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.
Burger MT, Knapp M, Wagman A, Ni ZJ, Hendrickson T, Atallah G, Zhang Y, Frazier K, Verhagen J, Pfister K, Ng S, Smith A, Bartulis S, Merrit H, Weismann M, Xin X, Haznedar J, Voliva CF, Iwanowicz E, Pecchi S. Burger MT, et al. Among authors: frazier k. ACS Med Chem Lett. 2010 Oct 13;2(1):34-8. doi: 10.1021/ml1001932. eCollection 2011 Jan 13. ACS Med Chem Lett. 2010. PMID: 24900252 Free PMC article.
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, Frazier K, Ng S, Smith A, Verhagen J, Haznedar J, Huh K, Iwanowicz E, Xin X, Menezes D, Merritt H, Lee I, Wiesmann M, Kaufman S, Crawford K, Chin M, Bussiere D, Shoemaker K, Zaror I, Maira SM, Voliva CF. Burger MT, et al. Among authors: frazier k. ACS Med Chem Lett. 2011 Aug 26;2(10):774-9. doi: 10.1021/ml200156t. eCollection 2011 Oct 13. ACS Med Chem Lett. 2011. PMID: 24900266 Free PMC article.
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, Lapointe GR, Feucht PH, Warne RL, Heise CC, Menezes D, Aardalen K, Ye H, He M, Le V, Vora J, Jansen JM, Wernette-Hammond ME, Harris AL. Renhowe PA, et al. Among authors: frazier k. J Med Chem. 2009 Jan 22;52(2):278-92. doi: 10.1021/jm800790t. J Med Chem. 2009. PMID: 19113866
Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
Frazier K, Jazan E, McBride CM, Pecchi S, Renhowe PA, Shafer CM, Taylor C, Bussiere D, He MM, Jansen JM, Lapointe G, Ma S, Vora J, Wiesmann M. Frazier K, et al. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2247-51. doi: 10.1016/j.bmcl.2006.01.020. Epub 2006 Jan 30. Bioorg Med Chem Lett. 2006. PMID: 16446087
Researcher and partner perspectives on the relationship between engagement in research and three uses of patient-centered comparative clinical effectiveness research study findings.
Maurer ME, Lavelle ME, Hilliard-Boone T, Frazier K, Agraviador D, Mosbacher R, Forsythe L, Carman KL. Maurer ME, et al. Among authors: frazier k. Res Involv Engagem. 2024 Oct 14;10(1):105. doi: 10.1186/s40900-024-00632-9. Res Involv Engagem. 2024. PMID: 39402691 Free PMC article.
209 results